Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)

Multiple System Atrophy (MSA) Clinical Trial

Official title:
Intermediate-Size Patient Population Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)

Status No longer available

Clinical Trial Summary

The purpose of this expanded access program is to provide access to the investigational drug verdiperstat in patients with Multiple System Atrophy (MSA). Expanded access allows patients with a serious or a life-threatening disease or condition access to an investigational drug when no satisfactory approved treatment options are available.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05086094
Study type	Expanded Access
Source	Biohaven Pharmaceuticals, Inc.
Contact
Status	No longer available
Phase

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05923866` - A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy	Phase 2
Recruiting	`NCT02778607` - PROgressive Supranuclear Palsy CorTico-Basal Syndrome Multiple System Atrophy Longitudinal Study UK
Completed	`NCT01485549` - Oligomeric Alpha-synuclein in Multiple System Atrophy
Completed	`NCT02796209` - Norepinephrine Transporter Blockade, Autonomic Failure	Phase 2
Recruiting	`NCT03811808` - Multiple System Atrophy Multidisciplinary Clinic
Completed	`NCT04193527` - A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients	Phase 3
Completed	`NCT01888185` - Identifying Biomarkers of Parkinson's Disease Using Magnetic Resonance Imaging (MRI)